Julia di Iulio

T‑cell engagers have delivered clear clinical benefit in hematologic malignancies, yet broader application, particularly in solid tumours and autoimmune diseases, has been limited by safety and efficacy barriers. This session will explore how next‑generation engineering strategies are helping to overcome these challenges.

• Addressing tumour heterogeneity and antigen escape through multi‑specific designs, affinity tuning, and improved target selection
• Overcoming the immunosuppressive tumour microenvironment, which limits T‑cell activation and persistence in solid tumours
• Mitigating cytokine release syndrome (CRS) by refining CD3 binding, format, valency, and dosing strategies
• Reducing on‑target, off‑tumour toxicity via conditional activation, masking approaches, and improved tumour selectivity
• Showcasing recent clinical success stories in solid tumours enabled by rational TCE engineering